|Bid||507.11 x 1100|
|Ask||507.60 x 1000|
|Day's Range||489.39 - 507.11|
|52 Week Range||383.12 - 553.29|
|Beta (5Y Monthly)||0.88|
|PE Ratio (TTM)||31.48|
|Earnings Date||Apr 13, 2022 - Apr 18, 2022|
|Forward Dividend & Yield||5.80 (1.19%)|
|Ex-Dividend Date||Mar 11, 2022|
|1y Target Est||567.21|
Hologic's (HOLX) two new molecular assays monitor transplant patients for EBV and BKV.
A strong procedure recovery in the hospital business, the resilience of blood donors in blood centers, and rollouts of Persona technology and NexSys aid Haemonetics (HAE).
NewCo is expected to operate successfully, leveraging Medtronic's (MDT) capabilities as a healthcare technology leader and DaVita's deep expertise as a comprehensive kidney care provider.